{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-041317","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2023-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.984063+00:00","generated_at":"2026-06-07T14:16:27.066824+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"C4 Therapeutics announces positive Phase 1 data for CFT7455 in relapsed/refractory multiple myeloma","bullets":["Monotherapy dose escalation complete; 22 patients, median 7 prior therapies; 1 PR at 75 µg daily in BCMA-refractory patient.","Combination with dexamethasone: 9 patients; 1 sCR and 1 PR at 37.5 µg daily, both BCMA refractory.","CFT7455 well tolerated; no DLTs leading to discontinuation; common Grade 3+ AE: neutropenia (n=11).","Optimal dosing schedule 14 days on/14 days off; immunomodulatory CD8+ T-cell activation observed.","Dose escalation continues for combination and NHL; full Phase 1 data expected in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-041317","json":"https://secwatch.observer/filing/0001628280-23-041317.json","markdown":"https://secwatch.observer/filing/0001628280-23-041317.md","text":"https://secwatch.observer/filing/0001628280-23-041317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023041317/0001628280-23-041317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023041317/cccc-20231212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:16:27.066824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}